2027 Medicare Part D Changes: What Agents Must Review Before AEP
- 15 hours ago
- 6 min read
Prepare for Medicare Part D AEP 2026
Review 2027 Medicare Part D changes before Annual Enrollment Period begins.
AEP runs from October 15 through December 7, 2026, for coverage beginning January 1, 2027. During this period, beneficiaries can compare and change Medicare Advantage and stand-alone Part D coverage.
The 2027 benefit structure continues the Inflation Reduction Act redesign. CMS is codifying several changes that previously operated through annual program instructions. The Contract Year 2027 Medicare Advantage and Part D Final Rule confirms the elimination of the coverage gap, the reduced annual out-of-pocket threshold, $0 catastrophic-phase cost sharing, and related calculation and operational changes.
Use the final 2027 plan materials, not assumptions based on a client’s current plan. Review each plan’s Annual Notice of Change, Evidence of Coverage, formulary, pharmacy network, utilization management rules, and premium.
Explain the three-phase Part D benefit
The coverage gap, commonly called the donut hole, no longer exists. The standard Part D benefit has three primary phases:
Deductible phase.
Initial coverage phase.
Catastrophic phase.
For 2027, the defined standard Part D deductible is $700. Individual plans may use a lower deductible or no deductible. Confirm the actual deductible for every plan under review.
The annual out-of-pocket threshold for covered Part D drugs is $2,400 in 2027. This threshold applies to qualifying out-of-pocket spending for covered formulary medications. Premiums do not count toward the threshold.
After the beneficiary reaches the $2,400 threshold, the beneficiary pays $0 cost sharing for covered Part D drugs during the remainder of the calendar year. The threshold is indexed and can change annually. Explain the difference between the 2026 threshold and the 2027 threshold without presenting the amount as a permanent cap.
The redesign improves protection for people with high drug costs. It does not make every plan identical. A beneficiary may still face different deductibles, copays, coinsurance, tiers, pharmacy pricing, and coverage restrictions before reaching the catastrophic phase.
Review the medication list before comparing plans
Start every plan review with a complete medication list.
Request the following information for each prescription:
Exact drug name.
Generic or brand name.
Strength.
Dosage and frequency.
Quantity per fill.
Current pharmacy.
Prescribing provider.
Mail-order use.
Recent prescription changes.
Include insulin, specialty drugs, injectable medications, vaccines, and drugs obtained through mail order or specialty pharmacies. Include medications the client expects to start after a scheduled procedure or diagnosis, but do not assume coverage until the plan confirms it.
Ask the client whether the medication list is current. Remove discontinued prescriptions. Confirm whether the client uses a generic equivalent, receives samples, splits tablets, or fills a prescription through a manufacturer assistance program. These details can affect the plan comparison.
Do not recommend changing a medication, dosage, or treatment. Ask the client to consult the prescribing provider about clinical alternatives. Your role is to compare coverage and costs using the client’s current treatment information.
Use a client’s medication list to identify the total cost of a plan, not only the monthly premium. A plan with a low premium may produce higher prescription costs. A plan with a higher premium may provide better coverage for a specific brand or specialty medication. Compare the full cost pattern across the year.
Check formularies, tiers, and utilization management
A formulary identifies the drugs covered by a Part D plan. It also identifies the tier assigned to each covered drug. Tiers generally influence the member’s copay or coinsurance.
Common tier categories include preferred generics, generics, preferred brands, non-preferred drugs, specialty drugs, and vaccines. Plan names and tier structures vary. Never compare tier labels without reviewing the plan’s actual cost-sharing requirements.
Check for changes between 2026 and 2027:
Drug removed from the formulary.
Drug moved to a higher tier.
Brand drug replaced by a generic requirement.
New quantity limits.
New prior authorization requirements.
New step therapy requirements.
Specialty pharmacy requirement.
Different mail-order rules.
Different insulin or vaccine treatment.
Drug utilization management can control access and cost. Prior authorization requires approval before the plan covers a medication. Step therapy requires the member to try another covered drug first. Quantity limits restrict the amount covered during a specific period. These rules can apply even when the drug appears on the formulary.
Review utilization management requirements for every medication that materially affects the client’s health or annual drug costs. If a client has an established treatment plan, explain that a plan’s coverage rule may require additional documentation or a prescriber response.
The CY 2027 Final Part D Bidding Instructions direct sponsors to submit formulary information to CMS for review. The instructions also address prior authorization criteria and CMS’s effort to reduce overly burdensome diagnostic requirements. Carrier-specific documents remain necessary because CMS approval does not make every plan’s formulary or utilization management process the same.
Verify preferred pharmacies and actual access
Pharmacy network design can change a prescription comparison.
A preferred pharmacy may offer lower cost sharing than a standard network pharmacy. A mail-order option may reduce the cost for maintenance medications. A specialty pharmacy may be required for certain high-cost drugs.
Ask where the client fills prescriptions now. Check whether that pharmacy remains in-network and preferred for 2027. Verify each location, including pharmacies used in a second residence or during seasonal travel.
Compare at least two scenarios when practical:
Current pharmacy.
Preferred retail pharmacy.
Mail-order pharmacy.
Specialty pharmacy, if applicable.
A plan with a lower premium may not be the lowest-cost option if the client uses a non-preferred pharmacy. A preferred pharmacy may lower cost sharing but may be less convenient or less available in the client’s area. Explain the trade-off and allow the client to weigh cost against access.
Explain the Medicare Prescription Payment Plan
The Medicare Prescription Payment Plan allows eligible Part D and Medicare Advantage prescription drug plan members to spread covered prescription drug cost sharing across monthly payments.
The option is voluntary and does not reduce the total cost of covered medications. It changes the timing of payment. The member still pays the plan premium, if applicable, and remains responsible for cost sharing under the plan.
The payment plan can help a beneficiary who expects a large prescription expense early in the year. For example, a client taking a high-cost specialty medication may face substantial cost sharing after the deductible. The payment plan can spread that expense through monthly bills instead of requiring the full amount at the pharmacy counter.
The arrangement can also create budgeting concerns. A member may receive a lower pharmacy bill but a higher monthly plan bill later. Explain the billing obligation clearly. Direct the client to the plan for enrollment, monthly payment calculations, billing questions, and cancellation procedures.
Do not describe the payment plan as a discount, subsidy, or premium reduction. Review the plan’s official materials and the CMS Medicare Prescription Payment Plan resources before discussing program details.
Apply the changes to client-review examples
Consider a client taking four generic maintenance medications. Plan A has a higher premium but lists all four drugs on a preferred generic tier at a preferred pharmacy. Plan B has a lower premium but places one medication on a higher tier and offers less favorable retail cost sharing. Plan B may appear better in a premium-only comparison. The medication and pharmacy review may show a different annual result.
Consider a client taking one high-cost specialty medication. Confirm the drug’s formulary status, specialty tier, coinsurance, prior authorization, quantity limits, and required pharmacy. Estimate the client’s costs before reaching the $2,400 threshold. Explain that the catastrophic phase provides $0 cost sharing after the threshold for covered Part D drugs, but it does not eliminate premiums or guarantee coverage for a drug excluded from the formulary.
Consider a client whose drug moves from a preferred brand tier to a non-preferred tier. Confirm whether the plan requires prior authorization or step therapy. Ask the client to contact the prescribing provider about clinical options if needed. Do not represent a formulary change as a reason to stop treatment.
Use these examples to explain trade-offs. Avoid promising a specific annual cost until the plan’s 2027 materials and the client’s complete medication information are verified.
Complete Medicare agent training before AEP
Update your Medicare carrier certifications before discussing 2027 plans. Review carrier-specific formularies, pharmacy networks, benefit summaries, sales presentations, enrollment procedures, and compliance instructions.
Complete a documented needs analysis for each client. Follow the required compliant sale process. Record the medication list, pharmacies reviewed, plans considered, client questions, and final enrollment decision according to applicable carrier and CMS requirements.
For official eligibility and enrollment information, review the CMS Part D plans and enrollment resources. Confirm election-period rules before submitting an application.
Use a repeatable 2027 review process
Create one standard AEP workflow:
Collect and verify the medication list.
Confirm current and preferred pharmacies.
Compare 2026 and 2027 formularies.
Review tiers and utilization management.
Compare deductible, copays, coinsurance, premium, and estimated annual drug costs.
Explain the $2,400 out-of-pocket threshold.
Explain the Medicare Prescription Payment Plan when relevant.
Review the plan’s ANOC and Evidence of Coverage.
Document the comparison and client decision.
Submit the enrollment application through the approved process.
The 2027 Medicare Part D changes make medication-level plan review essential. Elimination of the coverage gap and $0 catastrophic-phase cost sharing improve protection for high drug costs, but plan differences remain significant. Prepare with current carrier materials, official CMS guidance, and a complete client medication review.
This article provides general educational information for insurance professionals. It does not provide individualized legal, tax, medical, or financial advice. Refer clients to their plan, pharmacist, prescriber, or appropriate professional for questions outside the scope of plan comparison and enrollment.
Official resources
Comments